Domatinostat

Domatinostat

SCHEMBL30477018

Cn1cc(-c2ccc(S(=O)(=O)n3ccc(/C=C/C(=O)Nc4ccccc4N)c3)cc2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 1.00
HDAC2 Q92769 12/20 1.00
HDAC3 O15379 4/20 1.00
HDAC10 Q969S8 2/20 1.00
HDAC11 Q96DB2 2/20 1.00
HDAC9 Q9UKV0 2/20 1.00
KDM1A O60341 1/20 1.00
HDAC6 Q9UBN7 2/20 0.51
ABL1 P00519 1/20 0.51
EGFR P00533 1/20 0.51
ERBB2 P04626 1/20 0.51
INSR P06213 1/20 0.51
PDGFRB P09619 1/20 0.51
CDK2 P24941 1/20 0.51
PLK1 P53350 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Domatinostat SCHEMBL1613943 1.00 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1613939 1.00 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1614631 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1614668 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1613924 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1614634 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1614665 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL31096918 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL1613921 0.99 HDAC1 (0.98) HDAC1HDAC2HDAC3HDAC10HDAC11
Domatinostat SCHEMBL31096922 0.98 HDAC1 (0.97) HDAC1HDAC2HDAC3HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 EP claimed
EP-2262775-B1 (E)-N-(2-AMINO-PHENYL)-3-{1-[4-(1-METHYL-1H-PYRAZOL-4-YL)-BENZENESULFONYL]-1H-PYRROL-3-YL}-ACRYLAMIDE SALTS 4SC AG (DE) 2024-09-04 EP claimed
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment 4SC AG (DE) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC2 11/4885HDAC3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.